Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03066193 · ClinicalTrials.gov registry record · Phase 2
Efficacy of a Therapeutic Combination of Dronabinol and PEA for Tourette Syndrome
A Phase 2 study, sponsored by Yale University.
- Completed
- Registry status
- Phase 2
- Development phase
- 17
- Enrollment target
NCT03066193 is a Phase 2 study that has completed, run by Yale University. The registered enrollment target is 17 participants.
The verdict
NCT03066193, a Phase 2 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 17 participants
- Enrollment target
Study Summary
This is an investigator-initiated proof of concept study with the purpose to examine the safety, tolerability and feasibility of Dronabinol (synthetic Δ9-THC) and PEA for the treatment of adults with Tourette syndrome.
Interventions
- DRUG Dronabinol and Palmitoylethanolamide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2017-02-01 |
| Est. Completion | 2018-06-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03066193
The ClinicalTrials.gov registry entry for NCT03066193 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Dronabinol and Palmitoylethanolamide is the first listed.
NCT03066193 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03066193 about?
NCT03066193 is a clinical study titled "Efficacy of a Therapeutic Combination of Dronabinol and PEA for Tourette Syndrome". This is an investigator-initiated proof of concept study with the purpose to examine the safety, tolerability and feasibility of Dronabinol (synthetic Δ9-THC) and PEA for the treatment of adults with Tourette syndrome.
What is the current status of trial NCT03066193?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 17 participants. The study started on 2017-02-01. Estimated completion is 2018-06-28.
What interventions are being tested in trial NCT03066193?
The interventions under investigation include: Dronabinol and Palmitoylethanolamide (DRUG).
Who is sponsoring clinical trial NCT03066193?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.